Advertisement
INCY or JNJ or MRK
Which Stock Would AI Choose? Incyte Corporation (INCY) vs. Johnson & Johnson (JNJ) vs. Merck & Co (MRK) Stock Comparison
Key Takeaways
- INCY shares have shown volatility with a recent 6.5% decline amid strong Q4 revenue growth of 28% to $1.51B, bolstered by European approval for Zynyz.
- JNJ exhibits robust stability, up nearly 18% YTD and 50% over one year, supported by FDA approvals for cancer therapies like TECVAYLI.
- MRK trades with moderate gains of 11% YTD but faces headwinds from declining Gardasil sales, offset by Keytruda strength and Winrevair potential.
- JNJ leads in market cap at $587B with a P/E of 22, while INCY (P/E 15) and MRK (P/E 16) appear more attractively valued relative to growth prospects.
- All three benefit from oncology catalysts, but JNJ's diversified portfolio provides superior risk-adjusted momentum in recent market activity.
- Relative performance highlights JNJ's outperformance over the past year at 50%, compared to MRK's 28% and INCY's 35%.
Introduction
This stock comparison examines INCY, a biotech focused on oncology and inflammation; JNJ, a diversified healthcare giant; and MRK, a leader in pharmaceuticals with emphasis on vaccines and cancer treatments. Traders seeking growth in biotech versus stability in large-cap pharma, or investors eyeing oncology sector exposure amid recent regulatory wins and earnings beats, will find value here. Recent market activity underscores contrasts in momentum, valuation sensitivity, and pipeline catalysts, aiding decisions on relative performance in the current environment.
INCY Overview and Recent Performance
Incyte Corporation (INCY) specializes in small-molecule therapeutics for oncology, hematology, and inflammation, with flagship products like Jakafi and Opzelura driving revenue. In recent market activity, shares experienced a roughly 6.5% pullback amid broader biotech volatility, trading around $96 with a market cap of $19B and trailing P/E of 15. Q4 2025 results showed 28% revenue growth to $1.51B, surpassing estimates despite an EPS miss, fueled by Jakafi sales up 7% and Opzelura demand. European Commission approval for Zynyz label expansion in oncology has boosted sentiment, alongside a 35% one-year gain, though short-term pressure reflects pipeline execution risks and higher expenses influencing performance.
JNJ Overview and Recent Performance
Johnson & Johnson (JNJ) operates across innovative medicine, medtech, and consumer health, with a market cap exceeding $587B and trailing P/E of 22. Shares have risen about 18% YTD and 50% over the past year, trading near $244, reflecting defensive strength amid market turbulence. Recent FDA approvals for TECVAYLI plus DARZALEX in blood cancer and EU nod for Akeega in prostate cancer have enhanced its oncology positioning. Ongoing talc litigation poses risks, but diversified revenue and reliable dividends have sustained positive sentiment and upward momentum in recent weeks.
MRK Overview and Recent Performance
Merck & Co (MRK) focuses on oncology, vaccines, and animal health, boasting a $289B market cap and trailing P/E of 16. Shares hover around $117, up 11% YTD but flat recently due to Gardasil sales declines and layoffs at a U.S. site. Keytruda continues as a blockbuster, with Q4 strength and Winrevair trial anticipation in pulmonary hypertension supporting growth outlook. Competitive pressures in vaccines and Keytruda patent concerns temper enthusiasm, contributing to subdued recent performance relative to peers.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform's top-performing AI trading bots from hundreds available, which collectively trade thousands of tickers using machine learning on 5-, 15-, and 60-minute timeframes. These bots earn their spotlight through AI-driven analysis highlighting superior adaptation to current market conditions like volatility in semiconductors, energy, and aerospace. Stats showcase impressive ranges: annualized returns up to +216%, win rates of 53-95%, profit factors reaching 8.99, and profit-to-drawdown ratios over 22. Diverse strategies span trend-following, hedging, and sector rotation, with trade durations from 1 day to 62 days. Traders can explore signal, virtual, or brokerage agents for copy trading. Visit Trending AI Robots to discover bots suited to today's dynamic markets.
Head-to-Head Comparison
INCY's biotech model emphasizes high-growth oncology pipelines like Zynyz, contrasting JNJ and MRK's diversified pharma portfolios with vaccines and medtech. Growth drivers differ: INCY relies on Jakafi/Opzelura expansion (28% recent revenue surge), MRK on Keytruda amid Gardasil weakness, and JNJ on broad approvals balancing litigation risks. Recent momentum favors JNJ (50% one-year return) over INCY (35%) and MRK (28%). Risks include INCY's volatility (beta 0.84), JNJ's lawsuits, and MRK's patent cliffs. Valuation sensitivity shows INCY and MRK cheaper on P/E versus JNJ, with sector exposure heaviest in oncology across all. Market sentiment tilts toward JNJ's stability amid trade-offs in growth versus defense.
Tickeron AI Verdict
Tickeron’s AI currently favors JNJ due to consistent upward trends, lower beta (0.33), superior one-year returns, and diversified catalysts like recent FDA/EU approvals, positioning it strongly relative to INCY's volatility and MRK's vaccine pressures. Probabilistic edge stems from stability and momentum, though INCY offers value for growth-oriented plays.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCY’s FA Score shows that 1 FA rating(s) are green whileJNJ’s FA Score has 3 green FA rating(s), and MRK’s FA Score reflects 4 green FA rating(s).
- INCY’s FA Score: 1 green, 4 red.
- JNJ’s FA Score: 3 green, 2 red.
- MRK’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCY’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 1 bullish TA indicator(s), and MRK’s TA Score reflects 4 bullish TA indicator(s).
- INCY’s TA Score: 4 bullish, 4 bearish.
- JNJ’s TA Score: 1 bullish, 6 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
INCY (@Biotechnology) experienced а +0.15% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -1.88% , and MRK (@Pharmaceuticals: Major) price fluctuated +0.46% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.86%. For the same industry, the average monthly price growth was -2.62%, and the average quarterly price growth was +6.54%.
Reported Earning Dates
INCY is expected to report earnings on Apr 28, 2026.
JNJ is expected to report earnings on Apr 14, 2026.
MRK is expected to report earnings on Apr 30, 2026.
Industries' Descriptions
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Major (-0.86% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| INCY | JNJ | MRK | |
| Capitalization | 19.1B | 574B | 300B |
| EBITDA | 1.76B | 41.1B | 28.3B |
| Gain YTD | -2.734 | 15.838 | 16.207 |
| P/E Ratio | 14.99 | 21.62 | 16.68 |
| Revenue | 5.14B | 94.2B | 65B |
| Total Cash | 3.58B | 20.1B | N/A |
| Total Debt | 40.4M | 47.9B | 49.3B |
INCY | JNJ | MRK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 59 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 22 Undervalued | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 72 | 9 | 45 | |
SMR RATING 1..100 | 32 | 27 | 25 | |
PRICE GROWTH RATING 1..100 | 48 | 42 | 16 | |
P/E GROWTH RATING 1..100 | 100 | 78 | 25 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (22) in the Pharmaceuticals Major industry is in the same range as MRK (23) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INCY (70) in the Biotechnology industry. This means that JNJ's stock grew similarly to MRK’s and somewhat faster than INCY’s over the last 12 months.
JNJ's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (45) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for INCY (72) in the Biotechnology industry. This means that JNJ's stock grew somewhat faster than MRK’s and somewhat faster than INCY’s over the last 12 months.
MRK's SMR Rating (25) in the Pharmaceuticals Major industry is in the same range as JNJ (27) in the Pharmaceuticals Major industry, and is in the same range as INCY (32) in the Biotechnology industry. This means that MRK's stock grew similarly to JNJ’s and similarly to INCY’s over the last 12 months.
MRK's Price Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as JNJ (42) in the Pharmaceuticals Major industry, and is in the same range as INCY (48) in the Biotechnology industry. This means that MRK's stock grew similarly to JNJ’s and similarly to INCY’s over the last 12 months.
MRK's P/E Growth Rating (25) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (78) in the Pharmaceuticals Major industry, and is significantly better than the same rating for INCY (100) in the Biotechnology industry. This means that MRK's stock grew somewhat faster than JNJ’s and significantly faster than INCY’s over the last 12 months.
| INCY | JNJ | MRK | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 63% | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 62% | 1 day ago 52% | 1 day ago 52% |
| Momentum ODDS (%) | 1 day ago 65% | 1 day ago 47% | 1 day ago 52% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 52% | 1 day ago 47% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 40% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 60% | 1 day ago 42% | 1 day ago 52% |
| Advances ODDS (%) | 3 days ago 61% | 3 days ago 44% | 10 days ago 52% |
| Declines ODDS (%) | 5 days ago 59% | 5 days ago 41% | 1 day ago 51% |
| BollingerBands ODDS (%) | 1 day ago 61% | N/A | 1 day ago 51% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 34% | 1 day ago 53% |
Advertisement